BioStem Announces Notice of Allowance for Two U.S. Patent Applications
BioStem Technologies (OTC: BSEM) has received Notice of Allowance from the USPTO for two patent applications, strengthening its intellectual property portfolio in advanced wound care technology. The company currently holds 43 issued patents and has 26 pending applications.
The first patent (No. 18/593,225) covers novel micronized human placental compositions for wound care, specifically designed for wound packing, irregular surfaces, weeping wounds, and dental/oral applications. The second patent (No. 18/290,914) pertains to sterile human placental allograft compositions manufactured with the BioRetain® process, aimed at treating conditions like diabetic foot ulcers and dental wounds.
BioStem Technologies (OTC: BSEM) ha ricevuto un Avviso di Concessione dall'USPTO per due domande di brevetto, rafforzando il suo portafoglio di proprietà intellettuale nella tecnologia avanzata per la cura delle ferite. Attualmente, l'azienda detiene 43 brevetti concessi e ha 26 domande in sospeso.
Il primo brevetto (No. 18/593,225) riguarda nuove composizioni micronizzate di placenta umana per la cura delle ferite, progettate specificamente per il riempimento delle ferite, superfici irregolari, ferite che sanguinano e applicazioni dentali/orali. Il secondo brevetto (No. 18/290,914) si riferisce a composizioni di allograft sterile di placenta umana prodotte con il processo BioRetain®, destinate a trattare condizioni come le ulcere del piede diabetico e le ferite dentali.
BioStem Technologies (OTC: BSEM) ha recibido un Aviso de Concesión de la USPTO para dos solicitudes de patente, fortaleciendo su cartera de propiedad intelectual en tecnología avanzada para el cuidado de heridas. Actualmente, la empresa posee 43 patentes emitidas y tiene 26 solicitudes pendientes.
La primera patente (No. 18/593,225) cubre composiciones micronizadas de placenta humana para el cuidado de heridas, diseñadas específicamente para el empaque de heridas, superficies irregulares, heridas exudativas y aplicaciones dentales/orales. La segunda patente (No. 18/290,914) se refiere a composiciones de aloinjertos de placenta humana estériles fabricadas con el proceso BioRetain®, destinadas a tratar condiciones como las úlceras del pie diabético y las heridas dentales.
BioStem Technologies (OTC: BSEM)는 USPTO로부터 두 개의 특허 출원에 대한 허가 통지를 받아, 고급 상처 치료 기술에 대한 지적 재산 포트폴리오를 강화했습니다. 현재 이 회사는 43개의 특허를 보유하고 있으며, 26개의 출원이 대기 중입니다.
첫 번째 특허(No. 18/593,225)는 상처 포장을 위해 특별히 설계된 인간 태반의 미세화된 조성을 다루고 있으며, 불규칙한 표면, 출혈이 있는 상처 및 치과/구강 응용을 포함합니다. 두 번째 특허(No. 18/290,914)는 BioRetain® 공정으로 제조된 무균 인간 태반 동종이식 조성과 관련이 있으며, 당뇨병성 발 궤양 및 치과 상처와 같은 상태를 치료하는 데 목적이 있습니다.
BioStem Technologies (OTC: BSEM) a reçu un Avis de Concession de l'USPTO pour deux demandes de brevet, renforçant ainsi son portefeuille de propriété intellectuelle dans la technologie avancée des soins des plaies. Actuellement, l'entreprise détient 43 brevets délivrés et a 26 demandes en attente.
Le premier brevet (No. 18/593,225) couvre des compositions micronisées de placenta humain pour les soins des plaies, spécifiquement conçues pour le remplissage des plaies, les surfaces irrégulières, les plaies suintantes et les applications dentaires/orales. Le second brevet (No. 18/290,914) concerne des compositions d'allogreffe de placenta humain stérile fabriquées avec le processus BioRetain®, visant à traiter des conditions telles que les ulcères du pied diabétique et les plaies dentaires.
BioStem Technologies (OTC: BSEM) hat von der USPTO eine Genehmigungsmitteilung für zwei Patentanträge erhalten, wodurch das geistige Eigentum im Bereich der fortschrittlichen Wundversorgung gestärkt wird. Das Unternehmen hält derzeit 43 erteilte Patente und hat 26 laufende Anträge.
Das erste Patent (Nr. 18/593,225) betrifft neuartige mikronisierte menschliche Plazentazusammensetzungen zur Wundversorgung, die speziell für das Wundpacken, unregelmäßige Oberflächen, nässende Wunden und zahnmedizinische/orale Anwendungen entwickelt wurden. Das zweite Patent (Nr. 18/290,914) bezieht sich auf sterile menschliche Plazenta-Allograft-Zusammensetzungen, die mit dem BioRetain®-Verfahren hergestellt werden und darauf abzielen, Zustände wie diabetische Fußgeschwüre und zahnmedizinische Wunden zu behandeln.
- Strengthened IP portfolio with two new patent allowances
- Proprietary BioRetain® process technology receives patent protection
- Expanded potential applications in wound care market
- None.
Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology
POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two of BioStem’s patent applications.
Jason Matuszewski, Chief Executive Officer of BioStem, stated: “BioStem is actively expanding its patent portfolio to accelerate product innovation and to drive development of new products that continue to elevate the standards of wound care. These newly granted patents will play a pivotal role in the development of next-generation products, further solidifying our position as a leader in the industry. BioStem’s robust intellectual property portfolio spans the wound care landscape, providing strong protection as we continue to introduce breakthrough solutions to the market and consider other regulatory pathways to strengthen our product positioning."
The USPTO has issued a Notice of Allowance for the following applications:
No. 18/593,225: MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEEN
The patent is directed to novel and inventive micronized human placental compositions for wound care. The unique method of preparing BioStem’s compositions results in optimal retention of the structural and molecular profile of the amnion and chorion tissue. These compositions can be used to develop products for wound packing, treatment of wounds having irregular surfaces/boundaries, weeping wounds, and dental/ oral wounds. These micronized compositions could even be integrated into a therapeutic bandage to support healing of a topical wound.
No. 18/290,914: STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF
The patent is directed to novel and inventive human placental allograft compositions manufactured with the BioRetain® process. The unique method of preparing these allograft compositions results in optimal retention of the structural and molecular profile of the amnion and chorion tissue thereby facilitating and supporting wound treatment when compared with conventional human placental allografts for the treatment of, for example, diabetic foot ulcers, dental wounds, and/or other topical wounds.
Mr. Matuszewski added: “The added protection for our proprietary BioREtain processing method bolsters the differentiation of this technology in the marketplace. We also intend to demonstrate the benefits of those differences to patients with ongoing benchtop and clinical studies.”
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow us on X and LinkedIn.
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2 ™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
For more information visit biostemtechnologies.com and follow us on X and LinkedIn.
Forward-Looking Statements:
Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
PCG Advisory
Adam Holdsworth
Phone: 917-497-9287
Email: adam@pcgadvisory.com
FAQ
What are the two new patent applications allowed for BioStem Technologies (BSEM)?
How many total patents does BSEM currently have in its portfolio?
What medical conditions can BSEM's new patented technologies treat?
What is unique about BSEM's BioRetain® process patent?
